BioCentury
ARTICLE | Company News

Actelion, Max Planck launch vaccine play Vaxxilon

June 27, 2015 12:42 AM UTC

Actelion Ltd. (SIX:ATLN) and the Max Planck Society launched Vaxxilon AG (Reinach, Switzerland), a newco focused on developing synthetic carbohydrate vaccines.

Vaxxilon licensed exclusive rights to multiple preclinical vaccine candidates against undisclosed targets from the Max Planck Society and plans to have its first candidate in the clinic within three years. Actelion will invest EUR 30 million ($34 million) into Vaxxilon over the next three to four years. ...